Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404332 · ClinicalTrials.gov registry record · Phase 1
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
A Phase 1 study, sponsored by Mohammed Milhem.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT07404332 is a Phase 1 study that is actively recruiting participants, run by Mohammed Milhem. The registered enrollment target is 35 participants.
The verdict
NCT07404332, a Phase 1 study, is actively recruiting participants, sponsored by Mohammed Milhem.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.
Interventions
- DRUG Pembrolizumab
- DRUG Cemiplimab
- DRUG Nivolumab
- DRUG 5 Azacytidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07404332
The ClinicalTrials.gov registry entry for NCT07404332 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT07404332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07404332 about?
NCT07404332 is a clinical study titled "5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors". This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.
What is the current status of trial NCT07404332?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2026-02-11. Estimated completion is 2031-02-28.
What interventions are being tested in trial NCT07404332?
The interventions under investigation include: Pembrolizumab (DRUG), Cemiplimab (DRUG), Nivolumab (DRUG), 5 Azacytidine (DRUG).
Who is sponsoring clinical trial NCT07404332?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.